These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 28536776

  • 1. Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.
    Abd Rahman AN, Tett SE, Abdul Gafor HA, McWhinney BC, Staatz CE.
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):993-1004. PubMed ID: 28536776
    [Abstract] [Full Text] [Related]

  • 2. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.
    Clin Pharmacokinet; 2009 Dec; 48(11):745-58. PubMed ID: 19817503
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [Abstract] [Full Text] [Related]

  • 4. Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.
    Yau WP, Vathsala A, Lou HX, Zhou S, Chan E.
    J Clin Pharmacol; 2009 Jun; 49(6):684-99. PubMed ID: 19386625
    [Abstract] [Full Text] [Related]

  • 5. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y, Naito T, Matsushita T, Otsuka A, Ushiyama T, Ozono S, Hishida A, Kagawa Y, Kawakami J.
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [Abstract] [Full Text] [Related]

  • 6. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J.
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil.
    Ling J, Shi J, Jiang Q, Jiao Z.
    Eur J Clin Pharmacol; 2015 Jan; 71(1):95-106. PubMed ID: 25327506
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.
    Colom H, Lloberas N, Andreu F, Caldés A, Torras J, Oppenheimer F, Sanchez-Plumed J, Gentil MA, Kuypers DR, Brunet M, Ekberg H, Grinyó JM.
    Kidney Int; 2014 Jun; 85(6):1434-43. PubMed ID: 24402086
    [Abstract] [Full Text] [Related]

  • 10. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients.
    van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot RA.
    Clin Pharmacokinet; 2009 Aug; 48(7):463-76. PubMed ID: 19691368
    [Abstract] [Full Text] [Related]

  • 12. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 13. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 14. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H, Felipe CR, Slade A, Schmouder RL, Medina Pestana JO.
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [Abstract] [Full Text] [Related]

  • 15. Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients.
    Punyawudho B, Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Avihingsanon Y, Vadcharavivad S.
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):272-80. PubMed ID: 22456298
    [Abstract] [Full Text] [Related]

  • 16. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE, Tett SE.
    Clin Pharmacokinet; 2007 Apr; 46(1):13-58. PubMed ID: 17201457
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis.
    Romano-Aguilar M, Reséndiz-Galván JE, Medellín-Garibay SE, Milán-Segovia RDC, Martínez-Martínez MU, Abud-Mendoza C, Romano-Moreno S.
    Lupus; 2020 Aug; 29(9):1067-1077. PubMed ID: 32539658
    [Abstract] [Full Text] [Related]

  • 19. Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients.
    Tornatore KM, Sudchada P, Dole K, DiFrancesco R, Leca N, Gundroo AC, Danison RT, Attwood K, Wilding GE, Zack J, Forrest A, Venuto RC.
    J Clin Pharmacol; 2011 Aug; 51(8):1213-22. PubMed ID: 21209244
    [Abstract] [Full Text] [Related]

  • 20. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.